Here you can find the list of Top German Pharmaceutical Companies which are sorted out based on the total sales in the recent year. Bayer is the largest pharma Company in Germany with a total sales of $51 Billion in the recent year.
List of Top German Pharmaceutical Companies
So here is the List of Top German Pharmaceutical Companies which are sorted out based on the total sales (Revenue).
1. Bayer AG
Bayer is the largest German Pharmaceutical Company based on the revenue. The company focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology.
- Revenue: $ 51 Billion
- ROE: 1%
- Debt/Equity: 1.3
- Employees: 100k
2. Merck KGaA
Merch is the 2nd largest German Pharmaceutical Company based on the total sales (Revenue). The Company discovers, develops, manufactures, and markets innovative pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis (MS), infertility, growth disorders, and certain cardiovascular and metabolic diseases.
- Revenue: $ 22 Billion
- ROE: 14 %
- Debt/Equity: 0.5
- Employees: 58k
Healthcare operates in four franchises: Neurology and Immunology, Oncology, Fertility, and General Medicine & Endocrinology. The Company R&D pipeline positions with a clear focus on becoming a global specialty innovator in oncology, immuno-oncology, neurology, and immunology.
Dermapharm is a fast-growing manufacturer of branded pharmaceuticals. The company, founded in 1991, is based in Grünwald near Munich. The company’s integrated business model includes in-house development and production as well as the sale of branded products by a pharmaceutically trained sales force.
- Revenue: $ 1 Billion
- ROE: 45 %
- Debt/Equity: 1.4
In addition to the main location in Brehna near Leipzig, Dermapharm operates other production, development and sales locations within Europe, primarily in Germany and the USA.
Dermapharm sells more than 1,300 drug approvals with over 380 active pharmaceutical ingredients in the “Branded Medicines and Other Health Products” segment. The range of drugs, medical products and dietary supplements specializes in selected therapeutic areas in which Dermapharm occupies a leading market position, especially in Germany.
Evotec has established itself as a global platform company, leveraging its data-driven multimodality platform for both proprietary as well as partnered research, and applying a unique combination of innovative technologies for the discovery and development of first-in-class and best-in-class pharmaceutical products.
Its network of partners includes all Top 20 Pharma and hundreds of biotechnology companies, academic institutions, and other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases.
- Revenue: $ 0.62 Billion
- ROE: 34 %
- Debt/Equity: 0.5
- Employees: 4k
Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and make them accessible to patients worldwide. To-date, the Company has established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.
Evotec operates globally with more than 4,000 highly qualified people at 14 sites in six countries across Europe and the USA. The Company’s sites in Hamburg (HQ), Cologne, Goettingen, and Munich (Germany), Lyon and Toulouse (France), Abingdon and Alderley Park (UK), Verona (Italy), Orth (Austria), as well as in Branford, Princeton, Seattle and Watertown (USA) offer highly synergistic technologies and services and operate as complementary clusters of excellence.
Biotest is a global supplier of plasma protein products and biotherapeutic drugs. Biotest products are primarily used in clinical immunology, hematology and intensive care medicine. They are used to treat people with serious and often chronic diseases in a targeted manner so that they can usually lead a largely normal life.
- Revenue: $ 0.6 Billion
- ROE: -7 %
- Debt/Equity: 1.2
- Employees: 2k
Biotest is a specialist in innovative hematology, clinical immunology and intensive care medicine. Biotest develops, produces and sells plasma proteins and biotherapeutic drugs. The value chain includes pre-clinical and clinical development through to global marketing. Biotest produces immunoglobulins, coagulation factors and albumins on the basis of human blood plasma, which are used in diseases of the immune system or the blood-forming systems. Biotest employs more than 1,900 people worldwide.
The most important raw material for pharmaceuticals is human blood plasma, which we process into effective and ultra-pure drugs in one of the most modern facilities in Europe. They are used in the therapy of life-threatening diseases such as blood clotting disorders (haemophilia), severe infections or disorders of the immune system.
Biotest’s production site is in Dreieich, Germany, at the company’s headquarters. Together with contractual partners, Biotest processes up to 1.5 million liters of blood plasma per year.
Biotest products are currently sold in more than 90 countries around the world. Biotest markets the products either through its own companies or in cooperation with local marketing partners or distributors.